LUKAS BIOMEDICAL INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Lukas’s core offering is its patented memory T‑cell immunotherapy (LuLym‑T), using advanced cell‑culture technology to expand and activate a patient’s own immune cells so they can recognize and destroy cancer cells — a treatment with low side effects, hig
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54318905
Status
Active
Number of Employees
0
Total Paid-in
Capital
418,743,710 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2020)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Lukas Biomedical is a Taiwanese biotechnology company focused on immunocellular therapy, committed to developing safe, effective cancer‑treatment solutions that improve patients’ quality of life — built by a team of clinicians and biomedical researchers under a patient‑centered philosophy.
The content above was translated by Ai
